Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

German Biopharmaceutical Partners to Seek Osteoarthritis Drug

By BiotechDaily International staff writers
Posted on 02 Dec 2013
Two German biopharmaceutical companies are joining forces to develop a new class of drugs for treatment of osteoarthritis.

At the present time there are no truly effective treatments for osteoarthritis of the knee, which, according to the World Health Organization, effects more than 5% of adults over the age of 40 (more than 30 million people) in the developed countries.

To boost the search for drugs to treat osteoarthritis, Biopharm GmbH (Heidelberg, Germany) and Merck Serono (Darmstadt, Germany) have agreed to embark on a two-year joint discovery program focused on a potential pro-anabolic osteoarthritis modifying drug based on a growth factor derived from Biopharm's growth factor platform technology.

According to the terms of the agreement, Biopharm will provide variants of a wild type protein, which is thought to drive hyaline joint cartilage formation during embryogenesis and seems to be associated with osteoarthritis, as well as early preclinical research services. In the event of identification of potential development candidates, Merck Serono will own exclusive development and commercialization rights.

“We have insight that the maternal protein shows an important role in joint cartilage formation. These findings raise hope that a modified wild type protein may induce cartilage regeneration in the osteoarthritic joint,” said Dr. Frank Plöger, CSO of Biopharm. “The alliance will draw on the combined expertise and resources of Merck Serono and Biopharm with the ultimate goal to develop a disease modifying osteoarthritis drug. Although we have knowledge about the molecule, we need a partner like Merck Serono, who does not only provide the necessary resources, but also know how best to set up of our research program to ensure a successful hand over to clinical experts.”

Related Links:

Biopharm GmbH
Merck Serono



Channels

Genomics/Proteomics

view channel
Image: Transmission electron micrograph of norovirus particles in feces (Photo courtesy of Wikimedia Commons).

Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.